Viridian Therapeutics, Inc\de Form 4 insider transactions

Director Jeffrey Robert Ajer acquired stock options for 32,341 shares of Viridian Therapeutics, Inc. common stock.

Jennifer K. Moses, a Director at Viridian Therapeutics, Inc., acquired stock options for 32,341 shares.

Sarah Gheuens, a Director at Viridian Therapeutics, Inc., acquired stock options on July 1, 2026, as detailed in a recent SEC Form 4 filing.

Fairmount Funds Management LLC, along with its associated entities, has reported a significant acquisition of common stock in Viridian Therapeutics, Inc.

Viridian Therapeutics' Chief Legal Officer, Jennifer Tousignant, received new equity grants and exercised existing restricted stock units, increasing her direct common stock ownership.

Viridian Therapeutics' Chief Financial Officer, Seth Harmon, reported new equity grants including stock options and restricted stock units, alongside the vesting and tax-related disposition of common stock.

Viridian Therapeutics' Chief Financial Officer Seth Harmon filed an amended Form 4 to correct his beneficial ownership, adding 1,711 shares of common stock acquired through an employee stock purchase plan.

Viridian Therapeutics' Chief Legal Officer, Jennifer Tousignant, filed an amended Form 4 to correct an omission of 610 shares purchased under the company's employee stock purchase plan.

Viridian Therapeutics' Chief Operating Officer, Thomas W. Beetham, reported significant equity grants of stock options and restricted stock units, alongside tax-related sales of common stock.

Viridian Therapeutics' President and CEO, Stephen F. Mahoney, reported the acquisition of substantial stock options and restricted stock units, alongside the vesting and tax-related disposition of common stock.

Viridian Therapeutics' Chief Medical Officer, Radhika Tripuraneni, received grants of 95,800 stock options and 19,150 restricted stock units.

Viridian Therapeutics' Chief Legal Officer, Jennifer Tousignant, reported a planned sale of 2,272 shares of common stock at $31.16 per share, effective December 31, 2025.

Fairmount Funds Management LLC and related entities reported an acquisition of 454,545 shares of Viridian Therapeutics common stock at $22 per share, increasing their indirect beneficial ownership to 3,914,458 shares.

Viridian Therapeutics, Inc. Director Christopher W. Cain was granted 21,000 stock options with an exercise price of $14.47, vesting by July 2026, as disclosed in a recent SEC Form 4 filing.

Viridian Therapeutics, Inc. Director Tomas Kiselak was granted 21,000 stock options with an exercise price of $14.47, vesting by July 2026, with beneficial ownership disclaimed due to an arrangement with Fairmount Funds Management LLC.

Viridian Therapeutics, Inc. Director Arlene Morris was granted 21,000 stock options with an exercise price of $14.47, vesting by July 2026.

Viridian Therapeutics, Inc. Director Jeffrey Robert Ajer was granted 21,000 stock options with an exercise price of $14.47, vesting by July 2026.

Viridian Therapeutics, Inc. Director Sarah Gheuens was granted 21,000 stock options with an exercise price of $14.47, vesting by July 2026 or the 2026 annual meeting.

Jennifer K. Moses, a Director at Viridian Therapeutics, Inc., was granted 21,000 stock options with an exercise price of $14.47, vesting over approximately one year.

Fairmount Funds Management LLC and its affiliates reported the exercise of stock options to acquire additional common stock in Viridian Therapeutics, Inc., increasing their indirect beneficial ownership.

Director Jeffrey Robert Ajer acquired 42,000 stock options in Viridian Therapeutics, Inc. on April 7, 2025.

Radhika Tripuraneni, Chief Medical Officer of Viridian Therapeutics, was granted stock options to purchase 310,700 shares of common stock.

Director Christopher W. Cain acquired stock options in Viridian Therapeutics, Inc. on March 10, 2025.

Jennifer Tousignant, Chief Legal Officer of Viridian Therapeutics, was granted stock options and restricted stock units on March 3, 2025, according to a Form 4 filing.

Stephen F. Mahoney, CEO of Viridian Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on March 3, 2025.

Thomas Beetham, Chief Operating Officer of Viridian Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on March 3, 2025.

Chief Financial Officer Seth Harmon reports the acquisition of stock options and restricted stock units in Viridian Therapeutics.

Thomas Beetham, Chief Operating Officer of Viridian Therapeutics, reports the acquisition of 5,000 shares of common stock at $23.41 per share.

Stephen Mahoney, President and CEO of Viridian Therapeutics, Inc., recently purchased 21,400 shares of common stock at a price of $23.33 per share.

Fairmount Funds Management, along with related entities, acquired 1,600,000 shares of Viridian Therapeutics at $18.75 per share, increasing their holdings to 3,445,813 shares.